Literature DB >> 29615459

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Bryan R Haugen1,2, Daniel W Bowles2,3, Nikita Pozdeyev4,5,2, Laurie M Gay6, Ethan S Sokol6, Ryan Hartmaier6, Kelsi E Deaver1, Stephanie Davis1,7, Jena D French1,2, Pierre Vanden Borre6, Daniel V LaBarbera2,8, Aik-Choon Tan2,3, Rebecca E Schweppe1,2, Lauren Fishbein1,5,2, Jeffrey S Ross6,9.   

Abstract

Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and therapeutic significance.Experimental Design: The genetic profiles of 583 advanced differentiated and 196 ATCs generated with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT and FoundationOne were analyzed.
Results: ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared with other thyroid cancer types. DNA mismatch repair deficit and activity of APOBEC cytidine deaminases were identified as mechanisms associated with high mutational burden in a subset of differentiated thyroid cancers and ATCs. Copy number losses and mutations of CDKN2A and CDKN2B, amplification of CCNE1, amplification of receptor tyrosine kinase genes KDR, KIT, and PDGFRA, amplification of immune evasion genes CD274, PDCD1LG2, and JAK2, and activating point mutations in small GTPase RAC1 were associated with ATC. An association of KDR, KIT, and PDGFRA amplification with the sensitivity of thyroid cancer cells to lenvatinib was shown in vitro Three genetically distinct types of ATCs are proposed.Conclusions: This large-scale analysis describes genetic alterations in a cohort of thyroid cancers enriched in advanced cases. Many novel genetic events previously not seen in thyroid cancer were found. Genetic alterations associated with anaplastic transformation were identified. An updated schematic of thyroid cancer genetic evolution is proposed. Clin Cancer Res; 24(13); 3059-68. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29615459      PMCID: PMC6030480          DOI: 10.1158/1078-0432.CCR-18-0373

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Authors:  Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

3.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

Review 4.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

5.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

6.  Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.

Authors:  Susi Barollo; Raffaele Pezzani; Andrea Cristiani; Marco Redaelli; Laura Zambonin; Beatrice Rubin; Loris Bertazza; Mariangela Zane; Carla Mucignat-Caretta; Alessandro Bulfone; Gianmaria Pennelli; Eric Casal Ide; Maria Rosa Pelizzo; Franco Mantero; Stefano Moro; Caterina Mian
Journal:  Thyroid       Date:  2014-01-23       Impact factor: 6.568

7.  Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.

Authors:  Leomar Y Ballester; Stephen F Sarabia; Hadi Sayeed; Nimesh Patel; Joshua Baalwa; Ioanna Athanassaki; Jose A Hernandez; Erica Fang; Norma M Quintanilla; Angshumoy Roy; Dolores H López-Terrada
Journal:  Pediatr Dev Pathol       Date:  2015-09-14

8.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

Authors:  Matthew T Chang; Saurabh Asthana; Sizhi Paul Gao; Byron H Lee; Jocelyn S Chapman; Cyriac Kandoth; JianJiong Gao; Nicholas D Socci; David B Solit; Adam B Olshen; Nikolaus Schultz; Barry S Taylor
Journal:  Nat Biotechnol       Date:  2015-11-30       Impact factor: 54.908

View more
  124 in total

1.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

2.  Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.

Authors:  Ana T Pinto; Marta Pojo; Joana Simões-Pereira; Ruben Roque; Ana Saramago; Lúcia Roque; Carmo Martins; Saudade André; José Cabeçadas; Valeriano Leite; Branca M Cavaco
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

Review 3.  Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Authors:  Mingzhao Xing
Journal:  Endocrinol Metab Clin North Am       Date:  2019-03       Impact factor: 4.741

4.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

5.  Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Authors:  Iñigo Landa; Nikita Pozdeyev; Christopher Korch; Laura A Marlow; Robert C Smallridge; John A Copland; Ying C Henderson; Stephen Y Lai; Gary L Clayman; Naoyoshi Onoda; Aik Choon Tan; Maria E R Garcia-Rendueles; Jeffrey A Knauf; Bryan R Haugen; James A Fagin; Rebecca E Schweppe
Journal:  Clin Cancer Res       Date:  2019-02-08       Impact factor: 12.531

6.  Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.

Authors:  Nicole M Iñiguez-Ariza; Sina Jasim; Mabel M Ryder; Ashish V Chintakuntlawar; John C Morris; Crystal R Hilger; Michael E Menefee; Robert C Smallridge; Nina J Karlin; Constanza Alcaino; Keith C Bible
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

7.  Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.

Authors:  Adam Stenman; L Samuel Hellgren; Kenbugul Jatta; Martin Hysek; Maja Zemmler; Renske Altena; Inga-Lena Nilsson; Robert Bränström; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

8.  The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

Authors:  Zongfu Pan; Lu Li; Yangyang Qian; Xinyang Ge; Xiaoping Hu; Yiwen Zhang; Minghua Ge; Ping Huang
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

9.  Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.

Authors:  Bin Xu; Talia Fuchs; Snjezana Dogan; Iñigo Landa; Nora Katabi; James A Fagin; R Michael Tuttle; Eric Sherman; Anthony J Gill; Ronald Ghossein
Journal:  Thyroid       Date:  2020-05-08       Impact factor: 6.568

Review 10.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.